vs
渤健（BIIB）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是罗致恒富的1.8倍（$2.3B vs $1.3B），罗致恒富同比增速更快（-5.8% vs -7.1%），渤健自由现金流更多（$468.0M vs $170.8M），过去两年渤健的营收复合增速更高（-0.2% vs -6.1%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
BIIB vs RHI — 直观对比
营收规模更大
BIIB
是对方的1.8倍
$1.3B
营收增速更快
RHI
高出1.4%
-7.1%
自由现金流更多
BIIB
多$297.2M
$170.8M
两年增速更快
BIIB
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $1.3B |
| 净利润 | $-48.9M | — |
| 毛利率 | 78.3% | 37.6% |
| 营业利润率 | -2.5% | 1.7% |
| 净利率 | -2.1% | — |
| 营收同比 | -7.1% | -5.8% |
| 净利润同比 | -118.3% | — |
| 每股收益（稀释后） | $-0.35 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBRHI
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $2.5B | $1.4B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | $2.4B | $1.4B | ||
| Q4 24 | $2.5B | $1.4B | ||
| Q3 24 | $2.5B | $1.5B | ||
| Q2 24 | $2.5B | $1.5B | ||
| Q1 24 | $2.3B | $1.5B |
净利润BIIBRHI
| Q4 25 | $-48.9M | — | ||
| Q3 25 | $466.5M | $42.9M | ||
| Q2 25 | $634.8M | $41.0M | ||
| Q1 25 | $240.5M | $17.4M | ||
| Q4 24 | $266.7M | — | ||
| Q3 24 | $388.5M | $65.5M | ||
| Q2 24 | $583.6M | $68.2M | ||
| Q1 24 | $393.4M | $63.7M |
毛利率BIIBRHI
| Q4 25 | 78.3% | 37.6% | ||
| Q3 25 | 73.4% | 37.2% | ||
| Q2 25 | 77.1% | 37.2% | ||
| Q1 25 | 74.1% | 36.9% | ||
| Q4 24 | 76.2% | 38.8% | ||
| Q3 24 | 74.1% | 39.0% | ||
| Q2 24 | 77.8% | 39.2% | ||
| Q1 24 | 76.3% | 38.1% |
营业利润率BIIBRHI
| Q4 25 | -2.5% | 1.7% | ||
| Q3 25 | 22.0% | 1.0% | ||
| Q2 25 | 28.1% | 0.1% | ||
| Q1 25 | 12.8% | 2.9% | ||
| Q4 24 | 11.9% | 4.7% | ||
| Q3 24 | 18.3% | 4.1% | ||
| Q2 24 | 28.3% | 5.1% | ||
| Q1 24 | 20.3% | 2.8% |
净利率BIIBRHI
| Q4 25 | -2.1% | — | ||
| Q3 25 | 18.4% | 3.2% | ||
| Q2 25 | 24.0% | 3.0% | ||
| Q1 25 | 9.9% | 1.3% | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 15.8% | 4.5% | ||
| Q2 24 | 23.7% | 4.6% | ||
| Q1 24 | 17.2% | 4.3% |
每股收益（稀释后）BIIBRHI
| Q4 25 | $-0.35 | $0.32 | ||
| Q3 25 | $3.17 | $0.43 | ||
| Q2 25 | $4.33 | $0.41 | ||
| Q1 25 | $1.64 | $0.17 | ||
| Q4 24 | $1.82 | $0.53 | ||
| Q3 24 | $2.66 | $0.64 | ||
| Q2 24 | $4.00 | $0.66 | ||
| Q1 24 | $2.70 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $464.4M |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $1.3B |
| 总资产 | $29.4B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBRHI
| Q4 25 | — | $464.4M | ||
| Q3 25 | — | $365.3M | ||
| Q2 25 | — | $380.5M | ||
| Q1 25 | — | $342.5M | ||
| Q4 24 | — | $537.6M | ||
| Q3 24 | — | $570.5M | ||
| Q2 24 | — | $547.4M | ||
| Q1 24 | — | $540.9M |
总债务BIIBRHI
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBRHI
| Q4 25 | $18.3B | $1.3B | ||
| Q3 25 | $18.2B | $1.3B | ||
| Q2 25 | $17.6B | $1.3B | ||
| Q1 25 | $17.0B | $1.3B | ||
| Q4 24 | $16.7B | $1.4B | ||
| Q3 24 | $16.4B | $1.5B | ||
| Q2 24 | $15.9B | $1.5B | ||
| Q1 24 | $15.2B | $1.5B |
总资产BIIBRHI
| Q4 25 | $29.4B | $2.9B | ||
| Q3 25 | $29.2B | $2.8B | ||
| Q2 25 | $28.3B | $2.8B | ||
| Q1 25 | $28.0B | $2.7B | ||
| Q4 24 | $28.0B | $2.9B | ||
| Q3 24 | $28.3B | $3.0B | ||
| Q2 24 | $26.8B | $2.9B | ||
| Q1 24 | $26.6B | $2.9B |
负债/权益比BIIBRHI
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $170.8M |
| 自由现金流率自由现金流/营收 | 20.5% | 13.1% |
| 资本支出强度资本支出/营收 | 1.9% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1B | $266.8M |
8季度趋势，按日历期对齐
经营现金流BIIBRHI
| Q4 25 | $511.9M | $182.5M | ||
| Q3 25 | $1.3B | $77.4M | ||
| Q2 25 | $160.9M | $119.4M | ||
| Q1 25 | $259.3M | $-59.3M | ||
| Q4 24 | $760.9M | $154.8M | ||
| Q3 24 | $935.6M | $129.6M | ||
| Q2 24 | $625.8M | $142.0M | ||
| Q1 24 | $553.2M | $-15.9M |
自由现金流BIIBRHI
| Q4 25 | $468.0M | $170.8M | ||
| Q3 25 | $1.2B | $63.6M | ||
| Q2 25 | $134.3M | $104.2M | ||
| Q1 25 | $222.2M | $-71.7M | ||
| Q4 24 | $721.6M | $140.5M | ||
| Q3 24 | $900.6M | $111.8M | ||
| Q2 24 | $592.3M | $129.6M | ||
| Q1 24 | $507.3M | $-27.7M |
自由现金流率BIIBRHI
| Q4 25 | 20.5% | 13.1% | ||
| Q3 25 | 48.4% | 4.7% | ||
| Q2 25 | 5.1% | 7.6% | ||
| Q1 25 | 9.1% | -5.3% | ||
| Q4 24 | 29.4% | 10.2% | ||
| Q3 24 | 36.5% | 7.6% | ||
| Q2 24 | 24.0% | 8.8% | ||
| Q1 24 | 22.1% | -1.9% |
资本支出强度BIIBRHI
| Q4 25 | 1.9% | 0.9% | ||
| Q3 25 | 1.8% | 1.0% | ||
| Q2 25 | 1.0% | 1.1% | ||
| Q1 25 | 1.5% | 0.9% | ||
| Q4 24 | 1.6% | 1.0% | ||
| Q3 24 | 1.4% | 1.2% | ||
| Q2 24 | 1.4% | 0.8% | ||
| Q1 24 | 2.0% | 0.8% |
现金转化率BIIBRHI
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | 1.80× | ||
| Q2 25 | 0.25× | 2.91× | ||
| Q1 25 | 1.08× | -3.42× | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | 1.98× | ||
| Q2 24 | 1.07× | 2.08× | ||
| Q1 24 | 1.41× | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
